Top 4 Breyanzi Manufacturers (2026 Audit Report)

H2: Market Trends for Breyanzi in 2026

As of the second half (H2) of 2026, Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy developed by Bristol Myers Squibb (BMS), is positioned within a rapidly evolving oncology market. Several key trends are shaping its commercial trajectory and clinical adoption:

1. Expansion in Indication and Line of Therapy
   By H2 2026, Breyanzi has solidified its role in second-line (2L) treatment for relapsed or refractory (R/R) large B-cell lymphoma (LBCL), following earlier FDA approvals based on the TRANSFORM trial. Real-world evidence and post-marketing studies increasingly support its use in earlier treatment lines, with ongoing phase III trials exploring frontline applications in high-risk patients. This shift is driving increased prescribing and payer coverage.

2. Competitive Landscape Intensification
   Breyanzi faces growing competition from other CAR T-cell therapies such as Yescarta (Kite/Gilead), Tecartus (Kite), and Carvykti (J&J/Legend), as well as emerging allogeneic (“off-the-shelf”) CAR-T platforms. However, Breyanzi differentiates itself through a favorable safety profile—particularly lower rates of severe cytokine release syndrome (CRS) and neurotoxicity—enhancing its appeal among community oncologists and treatment centers with limited CAR-T infrastructure.

3. Improved Access and Manufacturing Efficiency
   BMS has made significant strides in reducing vein-to-vein time through decentralized manufacturing and logistics enhancements. By H2 2026, Breyanzi’s average manufacturing turnaround is under 20 days—a critical improvement over earlier challenges—enabling broader access, especially in community settings. The company’s patient support program, including financial assistance and care coordination, further boosts uptake.

4. Biosimilar and Cost Pressures
   While no biosimilars directly threaten Breyanzi (as a personalized cell therapy), increasing scrutiny on pricing and cost-effectiveness is prompting BMS to negotiate value-based contracts with payers. Outcomes-based agreements tied to durable response and hospitalization rates are becoming more common, reflecting payer demand for accountability in high-cost therapies.

5. Global Expansion and Emerging Markets
   Breyanzi has gained regulatory approvals in key European markets (EU, UK) and Japan, with limited but growing adoption in Asia-Pacific and Latin America. Partnerships with regional centers of excellence and investment in cryo-logistics infrastructure are supporting international growth, although reimbursement hurdles persist in certain countries.

6. Pipeline Synergies and Combination Strategies
   BMS is actively evaluating Breyanzi in combination with other agents, including checkpoint inhibitors and targeted therapies (e.g., BTK inhibitors), to improve response durability. Early data from combination trials presented at major conferences in 2026 suggest potential for deeper and longer remissions, positioning Breyanzi as a backbone in multimodal regimens.

7. Shift Toward Outpatient Administration
   With improved safety and risk mitigation protocols, outpatient administration of Breyanzi is gaining traction in H2 2026. This trend reduces treatment costs and hospital burden, increases bed capacity, and improves patient quality of life—factors that are positively influencing provider and payer acceptance.

In summary, H2 2026 marks a pivotal phase for Breyanzi, characterized by broader clinical adoption, enhanced accessibility, and strategic differentiation in a crowded CAR-T market. While pricing and competition remain challenges, BMS’s focus on safety, real-world outcomes, and operational excellence positions Breyanzi for sustained growth in lymphoma care.

Common Pitfalls Sourcing Breyanzi: Quality and Intellectual Property Concerns

Sourcing Breyansi (lisocabtagene maraleucel), a CAR T-cell therapy developed by Bristol Myers Squibb, presents significant challenges, particularly regarding quality assurance and intellectual property (IP) rights. Given its highly personalized, complex manufacturing process and protected status, navigating these pitfalls is critical for healthcare providers, patients, and authorized distributors.

Quality-Related Pitfalls

1. Risk of Counterfeit or Substandard Products
Due to Breyanzi’s high cost and demand, there is a growing risk of counterfeit or illegally distributed batches entering unregulated supply chains. These products may lack proper sterility, viability, or correct genetic modification, posing severe safety risks including ineffective treatment or life-threatening adverse events such as cytokine release syndrome (CRS) or neurotoxicity.

2. Cold Chain and Handling Violations
Breyanzi is a living cell therapy requiring strict cryopreservation and a tightly controlled cold chain from manufacturing to administration. Sourcing through unauthorized or non-compliant channels increases the risk of temperature excursions, which can compromise cell viability and therapeutic efficacy. Improper thawing or handling further degrades product quality.

3. Lack of Chain of Identity and Chain of Custody
As an autologous therapy, each Breyanzi dose is uniquely manufactured for a single patient using their own T cells. Unauthorized sourcing risks misidentification or mix-ups, potentially resulting in a patient receiving cells from another individual—an unacceptable and dangerous error. Maintaining an unbroken chain of identity is essential and difficult to verify outside the approved network.

Intellectual Property-Related Pitfalls

1. Infringement of Patents and Regulatory Exclusivity
Breyanzi is protected by multiple patents covering its CAR construct, manufacturing process, and methods of use. Sourcing the product through unauthorized suppliers may involve infringement of these IP rights. Additionally, Breyanzi benefits from regulatory exclusivity (e.g., orphan drug exclusivity), meaning only the approved manufacturer can legally market it in jurisdictions like the U.S. and EU during the exclusivity period.

2. Unauthorized Manufacturing or Replication Attempts
Due to high demand and cost, there may be attempts to replicate or biosimilar development without licensing. However, CAR T-cell therapies like Breyanzi are not amenable to generic replication due to their personalized nature and complex manufacturing. Any attempt to produce a similar product without IP clearance risks legal action and patient harm.

3. Grey Market Distribution and Licensing Violations
Distribution of Breyanzi is tightly controlled through a restricted network of certified treatment centers. Sourcing from third parties or secondary markets may involve breaches of licensing agreements and distribution contracts, invalidating warranties and exposing buyers to legal liability and lack of manufacturer support.

Conclusion

Sourcing Breyanzi outside of authorized, certified channels exposes patients and institutions to serious quality failures and legal risks related to intellectual property. Ensuring product authenticity, maintaining cold chain integrity, preserving patient-specific identity, and respecting IP protections are non-negotiable. All stakeholders should engage exclusively with Bristol Myers Squibb–authorized distributors and certified treatment centers to ensure patient safety and regulatory compliance.

Logistics & Compliance Guide for Breyanzi (liso-cel)

This guide provides essential information on the logistics and regulatory compliance requirements for handling, storing, transporting, and administering Breyanzi (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy indicated for the treatment of relapsed or refractory large B-cell lymphoma.

Indication and Prescribing Information

Breyanzi is approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. Prescribers must be certified in the Breyanzi Risk Evaluation and Mitigation Strategy (REMS) program and only prescribe to patients who meet the approved indication and have undergone required pre-infusion evaluations.

REMS Program Requirements

Breyanzi is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Breyanzi REMS. This program is mandated to ensure safe use due to the risks of severe or life-threatening cytokine release syndrome (CRS) and neurologic toxicities. Healthcare providers must:
– Enroll in the Breyanzi REMS program
– Complete mandatory training on managing CRS and neurologic toxicities
– Counsel patients on the risks and signs/symptoms of adverse reactions
– Ensure patients are observed for at least 7 days at a certified healthcare facility post-infusion
– Provide patients with the FDA-approved Medication Guide

Chain of Identity and Chain of Custody

Maintaining the chain of identity (COI) and chain of custody (COC) is critical throughout the Breyanzi treatment process:
– Collection: Apheresis must be performed at a certified collection center, with proper patient identification and labeling of the leukapheresis product.
– Tracking: Each patient’s product is tracked using a unique identifier from apheresis through manufacturing and reinfusion.
– Verification: At every handoff point (collection, shipping, receipt, storage, preparation), identity verification must be performed by trained personnel using barcode scanning and dual checks.

Cryopreservation and Storage Conditions

Breyanzi is a cryopreserved autologous CAR T-cell product that must be stored under strict conditions:
– Store in vapor-phase liquid nitrogen at or below -150°C (-238°F)
– Use only dedicated, locked freezers or cryogenic storage tanks with continuous temperature monitoring and alarm systems
– Avoid storage in mechanical freezers unless specifically validated for this purpose
– Do not store at temperatures above -150°C for more than 48 hours
– Monitor and document temperatures regularly per institutional and regulatory requirements

Transportation Protocols

Transport of Breyanzi must maintain cryogenic conditions at all times:
– Use validated dry vapor shippers filled with liquid nitrogen to maintain temperatures below -150°C
– Ensure shippers are labeled with “Do Not Open” and “Biological Substance, Category B” (if applicable), along with patient-specific identifiers
– Shipments must include temperature monitoring devices with data logging capabilities
– Couriers must be trained in handling cryogenic materials and emergency procedures
– All shipments require advance notification and coordination between manufacturing site, courier, and receiving facility

Receipt and Inspection Procedures

Upon arrival at the treatment center:
– Inspect the shipper for damage and verify dry ice or liquid nitrogen levels
– Confirm the patient’s identity matches the product label using barcode scanning and dual verification
– Check temperature monitoring data to ensure product remained within required range
– Document receipt time, condition, and temperature data in the institutional tracking system
– Transfer product to long-term cryogenic storage within 30 minutes of receipt
– Report any deviations immediately to the manufacturer and within institutional safety protocols

Pre-Infusion Handling and Preparation

Prior to infusion:
– Retrieve product only when infusion is scheduled and all pre-conditioning chemotherapy has been administered
– Thaw Breyanzi according to manufacturer’s instructions using a validated water bath or thawing device
– Inspect for visual particulates or discoloration post-thaw; do not administer if abnormalities are observed
– Administer intravenously within 3 hours of thawing
– Do not refreeze or re-thaw the product

Adverse Event Reporting and Compliance

All healthcare facilities administering Breyanzi must comply with mandatory safety reporting:
– Report all cases of CRS, neurologic events, and other serious adverse reactions to the Breyanzi REMS and FDA via MedWatch
– Maintain records of patient consent, infusion details, and follow-up assessments for at least 15 years
– Participate in long-term follow-up studies as required by regulatory authorities (e.g., 15-year follow-up for secondary malignancies)

Training and Staff Certification

Only trained and REMS-certified personnel may handle, prepare, or administer Breyanzi. Required training includes:
– Breyanzi REMS certification for prescribers, pharmacists, and nurses
– Institutional training on cryogenic handling, emergency response, and infusion protocols
– Regular competency assessments and documentation of training records

Regulatory and Institutional Compliance

Healthcare institutions must:
– Maintain up-to-date accreditation for cellular therapy (e.g., FACT or AABB, if applicable)
– Conduct internal audits of Breyanzi handling procedures
– Ensure compliance with FDA, state, and institutional regulations
– Keep all documentation (REMS enrollment, training records, product tracking, adverse events) readily available for inspection

By adhering to this logistics and compliance guide, healthcare providers can ensure the safe and effective use of Breyanzi while meeting all regulatory and patient safety requirements.

Declaration: Companies listed are verified based on web presence, factory images, and manufacturing DNA matching. Scores are algorithmically calculated.